Have a feature idea you'd love to see implemented?
Let us know!
SPRY ARS Pharmaceuticals Inc
Price (delayed)
$13.38
Market cap
$1.3B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.51
Enterprise value
$1.26B
Silverback Therapeutics, Inc. operates as a biotechnology company. The Company discovers and develops novel and proprietary ImmunoTAC technology, which is designed to create potent therapeutic molecules that can be systemically
Highlights
ARS Pharmaceuticals's debt has plunged by 69% YoY and by 36% from the previous quarter
SPRY's EPS is up by 28% year-on-year but it is down by 9% since the previous quarter
The net income has increased by 20% YoY but it has decreased by 10% QoQ
ARS Pharmaceuticals's quick ratio has plunged by 62% from the previous quarter and by 43% YoY
ARS Pharmaceuticals's equity has decreased by 15% YoY and by 7% from the previous quarter
Key stats
What are the main financial stats of SPRY
Market
Valuations
Earnings
Shares outstanding
97.19M
Market cap
$1.3B
Enterprise value
$1.26B
Price to book (P/B)
6.45
Price to sales (P/S)
505.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
490.96
Revenue
$2.57M
EBIT
-$49.1M
EBITDA
-$49.04M
Free cash flow
-$46.03M
Per share
Balance sheet
Liquidity
EPS
-$0.51
Free cash flow per share
-$0.47
Book value per share
$2.07
Revenue per share
$0.03
TBVPS
$2.17
Total assets
$217.6M
Total liabilities
$16.62M
Debt
$102,000
Equity
$200.98M
Working capital
$192.17M
Debt to equity
0
Current ratio
12.56
Quick ratio
12.36
Net debt/EBITDA
0.81
Margins
Efficiency
Dividend
EBITDA margin
-1,909.7%
Gross margin
95.6%
Net margin
-1,912.1%
Operating margin
-2,356.2%
Return on assets
-21.8%
Return on equity
-22.6%
Return on invested capital
-29.7%
Return on capital employed
-24.4%
Return on sales
-1,912.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SPRY stock price
How has the ARS Pharmaceuticals stock price performed over time
Intraday
-1.25%
1 week
-5.17%
1 month
-19.98%
1 year
184.68%
YTD
144.16%
QTD
-7.72%
Financial performance
How have ARS Pharmaceuticals's revenue and profit performed over time
Revenue
$2.57M
Gross profit
$2.46M
Operating income
-$60.51M
Net income
-$49.1M
Gross margin
95.6%
Net margin
-1,912.1%
ARS Pharmaceuticals's net margin has soared by 99% YoY and by 79% from the previous quarter
ARS Pharmaceuticals's operating margin has surged by 99% YoY and by 79% QoQ
The net income has increased by 20% YoY but it has decreased by 10% QoQ
The company's operating income rose by 17% YoY but it fell by 7% QoQ
Growth
What is ARS Pharmaceuticals's growth rate over time
Valuation
What is ARS Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.45
P/S
505.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
490.96
SPRY's EPS is up by 28% year-on-year but it is down by 9% since the previous quarter
The price to book (P/B) is 47% higher than the last 4 quarters average of 4.4
ARS Pharmaceuticals's equity has decreased by 15% YoY and by 7% from the previous quarter
The price to sales (P/S) is 98% lower than the last 4 quarters average of 29549.4
Efficiency
How efficient is ARS Pharmaceuticals business performance
SPRY's return on sales has surged by 99% year-on-year and by 79% since the previous quarter
SPRY's return on invested capital is up by 34% year-on-year but it is down by 13% since the previous quarter
SPRY's ROE is down by 14% from the previous quarter but it is up by 7% YoY
The company's return on assets fell by 13% QoQ but it rose by 6% YoY
Dividends
What is SPRY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SPRY.
Financial health
How did ARS Pharmaceuticals financials performed over time
ARS Pharmaceuticals's total liabilities has surged by 147% QoQ and by 47% YoY
ARS Pharmaceuticals's quick ratio has plunged by 62% from the previous quarter and by 43% YoY
ARS Pharmaceuticals's debt is 100% less than its equity
ARS Pharmaceuticals's debt has plunged by 69% YoY and by 36% from the previous quarter
ARS Pharmaceuticals's equity has decreased by 15% YoY and by 7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.